Home  >  News
Msc_Apr22 Advertisement
6Sugar_Free_Sweetener.gif
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

Emergent BioSolutions gets PEI approval to market BioThrax vaccine in Germany to prevent anthrax disease

Rockville, Maryland
Monday, August 5, 2013, 16:00 Hrs  [IST]

Emergent BioSolutions Inc., a specialty pharmaceutical company,  has received the Paul-Ehrlich-Institut (PEI) approval for its marketing authorization application for BioThrax (Anthrax Vaccine Adsorbed) in Germany. BioThrax is the only vaccine licensed by the US Food and Drug Administration (FDA) for the prevention of anthrax disease.

“Emergent is pleased with this first marketing authorization of BioThrax within the European Union,” said Adam Havey, executive vice president and president of the biodefense division of Emergent BioSolutions. “Based on this regulatory approval we look forward to further expanding international registration of BioThrax within the EU to support member states’ efforts to protect their citizens against the threat of anthrax as a biological weapon.”

With this approval, BioThrax becomes the only anthrax vaccine approved by PEI for the prevention of anthrax disease. The marketing authorization approved by PEI provides for the administration of BioThrax in a three-dose schedule with boosters at three-year intervals recommended thereafter.

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is not licensed for use in a post-exposure setting. The safety and efficacy of BioThrax have not been established in pediatric or geriatric populations. Individuals are not considered protected until they have completed the three-dose primary immunization series. Vaccination with BioThrax may not protect all individuals.

BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 66 million doses of BioThrax to the US government and continues to deliver additional doses under active procurement contracts.

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats.


















Emergent BioSolutions Inc., a specialty pharmaceutical company,  has received the Paul-Ehrlich-Institut (PEI) approval for its marketing authorization application for BioThrax (Anthrax Vaccine Adsorbed) in Germany. BioThrax is the only vaccine licensed by the US Food and Drug Administration (FDA) for the prevention of anthrax disease.

“Emergent is pleased with this first marketing authorization of BioThrax within the European Union,” said Adam Havey, executive vice president and president of the biodefense division of Emergent BioSolutions. “Based on this regulatory approval we look forward to further expanding international registration of BioThrax within the EU to support member states’ efforts to protect their citizens against the threat of anthrax as a biological weapon.”

With this approval, BioThrax becomes the only anthrax vaccine approved by PEI for the prevention of anthrax disease. The marketing authorization approved by PEI provides for the administration of BioThrax in a three-dose schedule with boosters at three-year intervals recommended thereafter.

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is not licensed for use in a post-exposure setting. The safety and efficacy of BioThrax have not been established in pediatric or geriatric populations. Individuals are not considered protected until they have completed the three-dose primary immunization series. Vaccination with BioThrax may not protect all individuals.

BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 66 million doses of BioThrax to the US government and continues to deliver additional doses under active procurement contracts.

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |